Amplify Treatments, Testing and Advancements ETF
Data updated: 2024-08-27
C000245561 — Amplify Treatments, Testing and Advancements ETF. United States Mid Cap Growth Materials Equity. Holdings, fees, performance and SEC filings.
C000245561 Fund Overview
Amplify Treatments, Testing and Advancements ETF is a US ETF managed by Amplify ETF Trust, categorised as United States Mid Cap Growth Materials Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Amplify ETF Trust
- Category: United States Mid Cap Growth Materials Equity
- Assets under management: $9.24M
- SEC CIK: 0001633061
- SEC series ID: S000082275
- Share class ID: C000245561
C000245561 Investment Objective and Strategy
Amplify Treatments, Testing and Advancements ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Amplify ETF Trust.
Investment objective
The Amplify Treatments, Testing and Advancements ETF seeks investment results that generally correlate (before fees and expenses) to the total return performance of the Prime Treatments, Testing and Advancements Index (the Index).
Principal investment strategy
The Fund uses a passive or indexing approach to try to achieve the Funds investment objective. Unlike many investment companies, the Fund does not try to beat the Index and does not seek temporary defensive positions when markets decline or appear overvalued. Prime Treatments, Testing and Advancements Index Under normal circumstances, the Fund invests at least 80% of its net assets (plus borrowings for investment purposes) in U.S.-listed equity securities or American Depositary Receipts (ADRs) of Treatments, Testing and Advancements Companies (as defined below). In general, the Index seeks to be comprised of companies: i) performing advancements in research, development, and commercialization of treatments or vaccines for infectious diseases, or ii) engaged in the advancement of research, development, manufacturing, and provision of biological tests for patients.
Prime Indexes (the Index Provider) determines whether a company is a Treatments, Testing and Advancements Company based on the assessment of: i) if a company has one or more vaccines or treatments for infectious diseases in preclinical research, in any phase of U.S. Food and Drug Administration (FDA) clinical trials, or in commercial stage (i.e., capable of being manufactured for widespread use) and is classified by North American Industry Classification System as being in either a) the Pharmaceutical and Medicine Manufacturing industry, or b) the Research and Development in the Physical, Engineering, and Life Sciences industry; or ii) if a company derives more than 50% of its revenue from research, development, manufacturing, and provision of biological tests for patients. To qualify for inclusion in the Index, Treatments, Testing and Advancements Companies must have an operating company structure.
To be added to the Index, Treatments, Testing and Advancements Companies must have a minimum market capitalization of $100 million, must have an average daily value traded over the prior three-month period of $250,000 and must be listed on a U.S. exchange. Companies already included in the Index must have a minimum market capitalization of $50 million. The Index has a quarterly review in each March, June, September, and December, at which times the Index is reconstituted and rebalanced by the Index Provider. The composition of the Index and the constituent weights are determined on the two Thursdays before the second Friday of each March, June, September, and December (or the next business day if this is a non-business day). Component changes are made after the market close on the third Friday of each March, June, September, and December (or the next business day if the third Friday is not a business day) and become effective at the market opening on the next trading day.
Weighting. All components with a market capitalization greater than $15 billion (A MegaCap Component) are equally weighted within an aggregate weighting of 10%. The determination for whether a company is designated a MegaCap Component is made only at the time of that companys initial entry into the Index. The remaining constituents are then ranked from highest to lowest market capitalization, subject to the following constraints: (i) the top five components are weighted at 6% each and (ii) the remaining constituents are weighted based on their market capitalization subject to a 4% limit per security. As of December 31, 2023, the Index had 61 components. The Fund uses a replication strategy. A replication strategy is an indexing strategy that involves investing in the securities of the Index in approximately the same proportions as in the Index.
However, the Fund may utilize a representative sampling strategy with respect to the Index when a replication strategy might be detrimental to shareholders, such as when there are practical difficulties or substantial costs involved in compiling a portfolio of equity securities to follow the Index, in instances in which a security in the Index becomes temporarily illiquid, unavailable or less liquid, or as a result of legal restrictions or limitations (such as tax diversification requirements) that apply to the Fund but not the Index. The Fund rebalances its portfolio in accordance with its Index, and, therefore, any changes to the Indexs rebalance schedule will result in corresponding changes to the Funds rebalance schedule. The Index was initially created by the Index Provider. The Index Provider is not affiliated with the Fund, the Adviser or Toroso Investments, LLC (the Sub-Adviser).
The Index Provider does not make investment decisions, provide investment advice, or otherwise act in the capacity of an investment adviser to the Fund. The Index is calculated and maintained by Solactive AG, which is not affiliated with the Fund, the Adviser, the Sub-Adviser, or the Index Provider. Concentration Policy. The Fund will not concentrate its investments ( i.e. , invest more than 25% of the value of its total assets) in securities of issuers in any one industry or group of industries, except to the extent that the Index concentrates in an industry or group of industries. As of the date of this prospectus, the Index is concentrated in the biotechnology industry. Diversification Status. The Fund is classified as non-diversified under the Investment Company Act of 1940, as amended (the 1940 Act ).
C000245561 Holdings
Top 10 holdings of Amplify Treatments, Testing and Advancements ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Alnylam Pharmaceuticals Inc | 10.34% |
| First American Government Obli | 9.96% |
| Labcorp Holdings Inc | 6.52% |
| Quest Diagnostics Inc | 6.10% |
| BioNTech SE | 5.02% |
| Moderna Inc | 4.88% |
| Vaxcyte Inc | 4.41% |
| ImmunityBio Inc | 4.40% |
| Bio-Rad Laboratories Inc | 4.00% |
| Zai Lab Ltd | 3.86% |
C000245561 Portfolio Allocation
Asset-class allocation of Amplify Treatments, Testing and Advancements ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 98.9% |
| Cash & Equivalents | 11.2% |
C000245561 Costs and Fees
C000245561 costs about $68 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.68%
- Gross expense ratio: 0.68%
- Portfolio turnover: 55%
C000245561 Cashflows
Over the 12 months to 2024-06, Amplify Treatments, Testing and Advancements ETF had net outflows of $2.76M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2024-06 | −$1.01M |
| 2024-05 | $0 |
| 2024-04 | −$840.59K |
| 2024-03 | $0 |
| 2024-02 | −$907.67K |
| 2024-01 | $0 |
C000245561 Debt Constituents
No individual debt constituents are reported in Amplify Treatments, Testing and Advancements ETF's latest SEC N-PORT filing.
C000245561 Prospectus and SEC Filings
Official Amplify Treatments, Testing and Advancements ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Related funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.